Search research articles
Contact Us
Filters
Showing results (1-10 of 488) with videos related to
Page
of 49
Sort By:
British Journal of Cancer
|
March 25, 2021
No need for H<sub>2</sub>-antagonists in premedication regimens for paclitaxel infusions: less is more
Hans Gelderblom, Juliette Zwaveling
Expert Opinion on Investigational Drugs
|
November 30, 2020
Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib
Mahmoud Mohammadi, Hans Gelderblom
Current Opinion in Oncology
|
May 15, 2014
Current clinical trials for advanced osteosarcoma and soft tissue sarcoma
Stefan Sleijfer, Hans Gelderblom
Investigational New Drugs
|
May 7, 2011
The fate of camptothecin glycoconjugate: report of a clinical hold during a phase II study of BAY 56-3722 (formerly BAY 38-3441), in patients with recurrent or metastatic colorectal cancer resistant/refractory to irinotecan
Marije Slingerland, Hans Gelderblom
Expert Opinion on Investigational Drugs
|
December 5, 2008
Diflomotecan, a promising homocamptothecin for cancer therapy
Judith R Kroep, Hans Gelderblom
Clinical Sarcoma Research
|
October 11, 2014
Pneumothorax as adverse event in patients with lung metastases of soft tissue sarcoma treated with pazopanib: a single reference centre case series
Arie J Verschoor, Hans Gelderblom
Sarcoma
|
October 2, 2013
Osteosarcoma: lessons learned and future avenues
Ajay Puri, Norman Jaffe, Hans Gelderblom
Future Oncology (London, England)
|
July 24, 2020
Pexidartinib: first approved systemic therapy for patients with tenosynovial giant cell tumor
Hans Gelderblom, Michiel van de Sande
Clinical Sarcoma Research
|
November 9, 2016
Efficacy of pazopanib and sunitinib in advanced axial chordoma: a single reference centre case series
Astrid Lipplaa, Sander Dijkstra, Hans Gelderblom
Sarcoma
|
June 20, 2013
Osteosarcoma: evolution of treatment paradigms
Norman Jaffe, Ajay Puri, Hans Gelderblom
Page
of 49
Search research articles
Search
Showing results (1-10 of 488) with videos related to
Sort By:
Page
of 49
British Journal of Cancer
|
March 25, 2021
No need for H<sub>2</sub>-antagonists in premedication regimens for paclitaxel infusions: less is more
Hans Gelderblom, Juliette Zwaveling
Expert Opinion on Investigational Drugs
|
November 30, 2020
Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib
Mahmoud Mohammadi, Hans Gelderblom
Current Opinion in Oncology
|
May 15, 2014
Current clinical trials for advanced osteosarcoma and soft tissue sarcoma
Stefan Sleijfer, Hans Gelderblom
Investigational New Drugs
|
May 7, 2011
The fate of camptothecin glycoconjugate: report of a clinical hold during a phase II study of BAY 56-3722 (formerly BAY 38-3441), in patients with recurrent or metastatic colorectal cancer resistant/refractory to irinotecan
Marije Slingerland, Hans Gelderblom
Expert Opinion on Investigational Drugs
|
December 5, 2008
Diflomotecan, a promising homocamptothecin for cancer therapy
Judith R Kroep, Hans Gelderblom
Clinical Sarcoma Research
|
October 11, 2014
Pneumothorax as adverse event in patients with lung metastases of soft tissue sarcoma treated with pazopanib: a single reference centre case series
Arie J Verschoor, Hans Gelderblom
Sarcoma
|
October 2, 2013
Osteosarcoma: lessons learned and future avenues
Ajay Puri, Norman Jaffe, Hans Gelderblom
Future Oncology (London, England)
|
July 24, 2020
Pexidartinib: first approved systemic therapy for patients with tenosynovial giant cell tumor
Hans Gelderblom, Michiel van de Sande
Clinical Sarcoma Research
|
November 9, 2016
Efficacy of pazopanib and sunitinib in advanced axial chordoma: a single reference centre case series
Astrid Lipplaa, Sander Dijkstra, Hans Gelderblom
Sarcoma
|
June 20, 2013
Osteosarcoma: evolution of treatment paradigms
Norman Jaffe, Ajay Puri, Hans Gelderblom
Page
of 49